Consideration of combination therapy with both vorinostat and ultraviolet therapy for cutaneous T-cell lymphoma patients

Trial Profile

Consideration of combination therapy with both vorinostat and ultraviolet therapy for cutaneous T-cell lymphoma patients

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2016

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Oct 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
    • 01 May 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top